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cules that can be used to redirect T cell immune response
against antigens expressed on the surface of tumor cells.
Although promising, most current protocols expand engi-
neered T cells non-speciﬁcally using IL-2 and OKT3, which
decreases the frequency of transgenic populations over
time. Additionally, cell expansion using conventional cul-
tureware is complicated and labor intensive, which limits
the broader application of this therapy. With the grant
support from Production Assistance for Cell Therapy
(PACT), we assessed whether CAR T cell manufacture could
be optimized and streamlined by: (i) supplementing non-
speciﬁc stimuli (IL-2) with an artiﬁcial antigen presenting
cell (a-APC) engineered to express cognate antigen and co-
stimulatory molecules, and (ii) efﬁciently and rapidly
expanding cells in a simple and scalable gas permeable
culture device (G-Rex). As a proof of principle, we sought to
expand T cells engineered with a CAR targeting the prostate
cancer antigen, PSCA. We ﬁrst generated an a-APC cell line
by modifying K562 cells, which expressed a range of co-
stimulatory molecules including CD80, CD86, and 41BBL,
with a retroviral vector encoding the PSCA antigen. After
the co-culture of CAR-PSCA T cells with the irradiated
a-APC, we found that a-APCs co-expressing PSCA antigen,
CD80, and 41BBL were the most effective in inducing T cell
expansion, with a 1.9 fold increase in total cell numbers
when compared with CAR T cells expanded in the presence
of IL2 alone. We also saw an increase in the frequency of
transgenic CAR T cells which increased from 36.5% to 88.1%
after 10 days of culture. In contrast, the percentage of
transgenic T cells was sustained when cultured in the
presence of IL2 (36.5% on day 0 and 37.2% on day 10). Thus,
culture of CAR-T cells with antigen-expressing a-APCs not
only improves total cell output, but also enriches for
transgene-expressing. Next, to assess whether we could
scale up cell production we transferred the engineered
a-APCs and CAR-PSCA T cells (at a 2:1 ratio) into a static
GMP-compliant G-Rex with a surface area of 100cm2. In
these G-Rex devices, O2 and CO2 are exchanged across
a silicone membrane at the base, which allows for the
addition of an increased depth of medium above the cells.
These culture conditions have been shown to increase cell
output without increasing the number of cell doublings.
From an initial seeding density of 25E+06 CAR T cells, we
obtained a total of 2200-2500E+06 cells within 10 days of
culture. Thus, without any intervention we obtained a 93
fold increase in cell numbers using only 1 liter of T cell
culture media. We also observed an enrichment of trans-
genic T cells (from 33.2% to 81.7%, a 2.41.2 fold increase,
after 10 days of culture). Taken together the total T cell fold
expansion (93) and the enrichment for the transgene
(2.41.2), we calculate a 223.5111.6 fold expansion of CAR
T cells.164
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Background: Cytomegalovirus (CMV) continues to be an
important human pathogen in allogeneic hematopoietic
cell transplant (allo-HCT) recipients. Both CD4+ and CD8+
T cells are important for long-term control of the virus.
Identiﬁcation of CMV-speciﬁc T cell epitopes has primarily
focused on CD8+ T cell epitopes. Adoptive transfer of
CMV-speciﬁc CD4+ T cells has previously been associated
with prolonged protection from reactivation and CMV
disease.
Aims: To characterize the repertoire and restriction of CMV-
speciﬁc CD4+ T cell responses against immediate early
antigen 1 and 2 (IE1 and IE2) in 16 healthy, HLA-typed, CMV+
donors.
Methods: We performed IFN-g ELISPOT assays ex vivo on
PBMCs from CMV+ donors using 187 peptides (15 amino
acids long and overlapping 10 amino acids) spanning the
entire IE1 and IE2. These peptides were distributed into
individual microtiter wells, PBMCs from each donor were
added and incubated, and the resulting responses were
measured by IFN-g ELISPOT analysis. To validate the
peptide-speciﬁcity and to establish the phenotype of the
responding cells, peptides eliciting IFN-g release in the
ELISPOT analysis were subsequently used to stimulate
PBMCs in vitro for 12-14 days followed by ﬂow cytometric
intracellular cytokine secretion assay. For the identiﬁed
CD4+ T cell responses, peptide-MHC class II (MHCII) afﬁnity
measurements were used to suggest the most likely
restricting element(s) among the donors MHCII molecules.
To validate MHCII restriction element(s), MHCII tetramers
(TMR) were generated and used to label in vitro stimulated
PBMCs.
Results: We have identiﬁed 27 CD4+ T cell epitopes in IE1
and IE2; 19 of these are novel. Several CD4+ T cell epitopes
appeared to be immunodominant. Thus, one DRB1*0101-
restricted IE2 epitope was recognized by 5/5 DRB1*0101-
positive donors, two DRB1*0301-restricted epitopes, one in
IE2 and one in IE1, were recognized by 4/4 and 4/4
DRB1*0301-positive donors, respectively, and one
DRB5*0101-restricted IE1 epitope was recognized by 4/4
DRB5*0101-positive donors. Additional epitopes appear to be
immunodominant by functional analysis, but have not yet
been validated with MHCII TMRs.
Conclusions: We have found multiple novel CD4+ epitopes
in CMV IE1 and IE2 of which several have been validatedwith
MHCII TMRs. These epitopes could be used to explore the
reconstitution of CMV-speciﬁc CD4+ T cells following allo-
HCT, and they could represent promising candidates for
adoptive CD4+ T cell transfer.166
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